

PRECEPTORSHIP PROGRAMME

Colorectal Cancer

Multidisciplinary management, standards
of care and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

16-17 APRIL 2021

Co-Chairs

Andrés Cervantes, Spain
Dirk Arnold, Germany

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

16-17 April 2021

CO-CHAIRS: Andrés Cervantes, Spain
Dirk Arnold, Germany

SPEAKERS: Myriam Chalabi, Netherlands
Chiara Cremolini, Italy
Michel Ducreux, France
Eduardo García-Granero, Spain
Sara Lonardi, Italy
Erika Martinelli, Italy
Dominik Modest, Germany
Clara Montagut, Spain
Iris Nagtegaal, Netherlands
Luis Sabater, Spain
Inês Santiago, Portugal
Jenny Seligmann, United Kingdom
Noelia Tarazona Llaveró, Spain

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Friday, 16 April 2021

15:00-15:10 10'	Opening	Andrés Cervantes, ES
10'	Welcome from ESMO and introduction	Andrés Cervantes, ES
15:10-17:45 155'	SESSION 1 Early colon cancer	Chair/Moderator: Dirk Arnold, DE
20'	Understanding CRC biology: MSI, BRAF, RAS, immunoscore, and others - what are the drivers of the malignancy, and what do we have to understand?	Iris Nagtegaal, NL
15'	The surgeon's point of view: Standard(s) of surgical practice for resectable colorectal cancer (special issues on rectal cancer, laparoscopy, transanal TME and robotic-assisted surgery)	Eduardo García-Granero, ES
20'	Adjuvant treatment for colon cancer stage II and III: For whom, how intensive, and how long?	Sara Lonardi, IT
10'	Discussion	Faculty
16:15-16:30	Break	
15'	A look into the future: Will preoperative treatment replace the standard sequence in early colon cancer?	Jenny Seligmann, UK
15'	Another look into the future: Assessing the concept of minimal residual disease	Noelia Tarazona Llaverro, ES
15'	Imaging of rectal cancer: What does the clinician have to know today – and will AI impact the future?	Inês Santiago, PT
20'	After 2020: New Standards of care in localized rectal cancer	Andrés Cervantes, ES
10'	Discussion	Faculty
17:45-18:25 40'	SESSION 2 Case Discussion on Localized Disease	Chair/Moderator: Dirk Arnold, DE
40'	Participants clinical case discussion (4x10')	Faculty

Saturday, 17 April 2021

15:00-16:15 75'	SESSION 3 Planning first line treatment for advanced colorectal cancer	Chair/Moderator: Andrés Cervantes, ES
15'	What biomarkers do we need to properly plan first line treatment? The role of liquid biopsy	Clara Montagut, ES
15'	Selection of patients for different approaches for first line treatment	Chiara Cremolini, IT
20'	How to treat patients with oligometastatic disease?	Dirk Arnold, DE
15'	How to integrate liver surgery into first line treatment?	Luis Sabater, ES
10'	Discussion	Faculty

16:15-16:30	Break	
16:30-17:45 75'	SESSION 4 Treatment for specific groups of patients and second and further lines treatments	Chair/Moderator: Andrés Cervantes, ES
20'	Selection for second - and further line therapies	Dominik Modest, DE
15'	Treatment for advanced MSI high patients	Myriam Chalabi, NL
15'	Treatments for HER2 driven patients	Erika Martinelli, IT
15'	Managing toxicities during continuum of care for advanced colon cancer	Michel Ducreux, FR
10'	Discussion	Faculty
17:45-18:25 40'	SESSION 5 Clinical case discussion on Advanced Disease	Chair/Moderator: Andrés Cervantes, ES
40'	Participants clinical case discussion (4x10')	Faculty
18:25-18:35 10'	Conclusion and farewell	Andrés Cervantes, ES Dirk Arnold, DE

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion